Acepodia (KY) announced on the 8th that their developed cell therapy drug ACE1831 achieved the endpoints in the first dose group of the first phase of clinical trials. Five participants with non Hodgkin's lymphoma were enrolled in this dose group, among whom three completed the safety observation period defined in the clinical trial protocol and met the criteria for safety data review during dose escalation.
Read more
